News

Issued by Akeso, not Summit Therapeutics Inc.

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025 · Published on PR Newswire

It isn’t one of Summit Therapeutics Inc.’s news releases, so 6ix doesn’t show it on Summit Therapeutics Inc.’s page or send it as an alert.

Go to Summit Therapeutics Inc. on 6ix